PharmaFocus Today – Page 92 – media

New AHA Scientific Statement Reconsiders Moderate Alcohol Use in Relation to Cardiovascular Health

Several medical groups have concluded regular consumption of alcohol in any amount poses a health risk, but a new scientific statement from the American Heart Association (AHA) offered more qualified guidance. The premise that moderate alcohol use reduces cardiovascular risk has been widely accepted for decades. The authors of a 1993 editorial in The New England Journal of Medicine concluded “there now seems little doubt” that such a benefit exists. However, a review of the evidence in 2025 produced a more cautious summary. “Considering the level of evidence, it remains unknown whether drinking is part of a healthy lifestyle, and therefore, clinicians should reinforce healthy lifestyle behaviors such as regularly engaging in physical activity, avoiding tobacco use, and maintaining healthy body weight,” the AHA document stated. Complex Mix “Data from recent studies using new methodologies (eg, individual participant-level data meta-analysis and Mendelian randomization [MR]) have challenged the idea that ...
- Source: drugdu
- 173
- June 18, 2025
ADHD Stimulants Can Be Safely Prescribed Via Telehealth, Study Argues

By Dennis Thompson HealthDay ReporterMONDAY, June 16, 2025 (HealthDay News) — People with ADHD might be prescribed their meds remotely without increasing their risk of addiction, a new study says. Experts have worried that prescribing stimulants like Adderall through telehealth visits might increase substance abuse among people with attention-deficit/hyperactivity disorder (ADHD). But this study found no increased risk among ADHD patients prescribed their meds via telehealth versus those who got their scrips at an in-person visit, according to results published June 11 in the American Journal of Psychiatry. “Our study suggests that, generally, telehealth-based relationships – which make health care more accessible – can be safe and don’t increase the risk of substance use disorder,” lead researcher Dr. Vinod Rao, medical director of adult ambulatory psychiatry at Massachusetts General Hospital in Boston, said in a news release. For the study, researchers tracked nearly 8,000 patients treated for ADHD at Massachusetts ...
- Source: drugdu
- 194
- June 18, 2025
30 working day review channel will be opened

Innovative drug payment breaks through the ten-year road from “payment desert” to “trillion dollar blue ocean”. Pharmaceutical companies are at the moment of innovation: giants turn around, innovators seek gold On June 16th, the National Medical Products Administration released the “Announcement on Optimizing the Review and Approval of Clinical Trials for Innovative Drugs (Draft for Comments)” (hereinafter referred to as the “Draft for Comments”), which marks the beginning of a transformation that may reshape the development pattern of innovative drugs in China – the clinical trial review and approval cycle for core innovative drug varieties is expected to be compressed to 30 working days. Clinical trials are an important part of innovative drug development. The optimization of the clinical trial review and approval pilot for innovative drugs can significantly improve research and development efficiency, and is the key to China’s move towards becoming a global hub for innovative drug ...
- Source: drugdu
- 266
- June 18, 2025
Venture capital is the “navigator” of innovative drugs, not just a simple “money bag”

With the frequent occurrence of large-scale license out transactions, China’s innovative pharmaceutical industry is constantly proving its research and development capabilities in front of global capital and multinational pharmaceutical companies. The other side of the industry’s positive momentum is that primary market investment and financing transactions are still in a low period. Focusing on the field of innovative drugs, some companies have secured large global BD deals, while many others are still struggling on the path of financing. This means that China’s innovative pharmaceutical industry is entering a stage of differentiation – leading companies with clinical data, global vision, and financing capabilities are gradually breaking through, while most companies still face the dual test of survival and development. In June of this year, 21st Century Business Herald interviewed Xu Qian, Managing Partner and General Manager of Danlu Capital in Beijing, to discuss the role of venture capital in the ...
- Source: drugdu
- 251
- June 18, 2025
Boan Biopharma’s BA1302 receives FDA approval for clinical trials

On June 17, Boan Bio (06955) issued an announcement, announcing that its independently developed innovative antibody-drug conjugate BA1302 targeting CD228 has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials. 　　The drug is intended for the treatment of a variety of solid tumors and has been granted orphan drug designation by the FDA for squamous non-small cell lung cancer and pancreatic cancer. Currently, BA1302 is undergoing Phase 1 clinical trials in China, and its global progress is ahead of other similar research and development efforts. 　　BA1302 has shown excellent internalization activity and bystander effects in preclinical studies, and can effectively inhibit the growth of tumor models derived from various cancer patients, showing good therapeutic potential. In addition, compared with the marketed ADCs with MMAE as toxin, BA1302 has shown a longer half-life and better safety in crab-eating monkeys. The company will ...
- Source: drugdu
- 259
- June 18, 2025
First patients enrolled in Phase I clinical trial of Clover Biopharmaceuticals combination vaccine

On June 17, Clover Biopharmaceuticals (02197) issued an announcement announcing that its respiratory syncytial virus (RSV) + human metapneumovirus (hMPV) ± parainfluenzaThe Phase I clinical trial of the PIV3 combined vaccine candidate product has completed the enrollment of the first batch of subjects. 　　The vaccine candidates involved in this trial include SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), which are developed based on the company’s protein trimerization vaccine technology platform. 　　According to the announcement, the Phase I clinical trial results of Clover Biopharmaceuticals’ RSVPreF vaccine candidate product (SCB-1019) announced in October 2024 showed that the vaccine had potentially best-in-class immunogenicity and tolerability characteristics in 70 elderly subjects. 　　This clinical result provides support for the company’s subsequent joint development of hMPV and PIV3 vaccines. The current Phase I clinical trial of the combined vaccine candidate product will enroll up to 192 elderly subjects to evaluate its safety, reactogenicity and ...
- Source: drugdu
- 151
- June 18, 2025
When China’s innovative drugs enter a golden age

Amid the wave of changes in the global pharmaceutical industry, BD transactions are becoming a key engine for Chinese innovative pharmaceutical companies to break through. In 2025, BD transactions in the field of innovative drugs will show explosive growth. A deep game about technology, capital and market is unfolding, and Chinese innovative pharmaceutical companies are standing at the forefront of this change with their outstanding performance. The heat storm behind the data According to incomplete statistics, in May 2025 alone, at least six domestic innovative pharmaceutical companies officially announced BD transaction orders, and most of them were cross-border cooperation between Chinese and foreign pharmaceutical companies. This high frequency of transactions is not accidental, but a microcosm of the hot trend of innovative drug BD transactions in 2025. Data shows that from the beginning of 2025 to date, the total transaction amount of innovative drugs going overseas has reached US$45.5 billion, ...
- Source: drugdu
- 459
- June 18, 2025
The value of this CAR-T therapy is still increasing

In February 2024, AstraZeneca officially incorporated Gracell into the group, setting a precedent for MNCs to acquire Chinese biotechs on a large scale. Gracell is AstraZeneca’s first acquisition in the CAR-T track, with its outstanding technology and pipeline – FasTCAR and AZD0120 at its core. AZD0120 is a BCMA/CD19 dual-targeted CAR-T cell therapy developed based on the FasTCAR rapid production platform, which has the potential to become a new generation of treatment options for malignant blood tumors and autoimmune diseases. As one of the core pipelines in AstraZeneca’s cell therapy matrix, the development strategy and clinical progress of AZD0120 have attracted much attention. The field of autoimmunity has been “tempered and upgraded”, and its value continues to increase At the EULAR 2025 Annual Meeting, Gracell Biopharma announced for the first time the safety and preliminary efficacy data of the IIT study of AZD0120 for the treatment of refractory systemic lupus ...
- Source: drugdu
- 228
- June 18, 2025
New insights into gout management strategies and cardiovascular outcomes

The European Alliance of Associations for Rheumatology – recommends that serum urate should be maintained at <6 mg/dL (360 µmol/L) and <5 mg/dL (300 µmol/L) in those with severe gout. But despite available treatments, gout is still often underdiagnosed and its management remains suboptimal. At the 2025 annual EULAR congress in Barcelona, new data were presented on a range of topics around gout. Gout flares are associated with cardiovascular events. Treating gout to target serum urate level prevents flares, but whether such treatment can also prevent cardiovascular events is unknown. An abstract from Edoardo Cipolletta and colleagues explored whether achieving serum urate levels of less than 360 μmol/L within 1 year of the first prescription of urate-lowering therapy has an effect on the 5-year risk of major adverse cardiovascular events (MACE). The authors used English and Swedish primary-care data linked to hospitalisation and mortality records for over 116,000 patients. Overall, ...
- Source: drugdu
- 204
- June 17, 2025
How Technology can Ease the Path to New Treatments Without the Pain

|Advances in flow cytometry could enable researchers to uncover valuable insights about food allergies without allergen exposure.Food allergies affect an estimated 220 million people(Opens in a new window) around the world, the World Health Organization reports. In the United States alone, one in 13 children are living with life-threatening food allergies, according to the non-profit organization Food Allergy Research and Education (FARE(Opens in a new window)). A major milestone in this field was reached in 2024 when the U.S. Food and Drug Administration approved the first biologic to treat food allergies after accidental exposures, Xolair (omalizumab). While there are a handful of other food-allergy treatments in the development pipeline, including combinations of monoclonal antibodies and immune-boosting drugs, innovation in this field remains limited. Replacing dated and harmful methods One limitation holding back the development of new therapies for food allergies is that many commonly used research tools are outdated and ...
- Source: drugdu
- 221
- June 17, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.